Smith & Nephew


Sports medicine leads a good Q3 showing

26/11/19 -"Smith & Nephew reported Q3 19 top-line growth of 4% on an underlying basis – driven by Sports Medicine Joint Repair (+12.2%), Advanced Wound Devices (+15.4%), Knee Implants (+4.6%) and ENT ..."

Pages
54
Language
English
Published on
26/11/19
You may also be interested by these reports :
13/12/19
As Siemens Healthineers has said that it is not interested in buying Qiagen, Roche could emerge as one of the bidders for the Dutch firm from the ...

10/12/19
FY18/19 earnings were impacted by increasing investments into R&D and digitalisation, along with the higher than expected financial charges and tax ...

09/12/19
Sales growth was at a record high in FY18/19 on the back of new product launches in the ophthalmic devices and microsurgery segments. While the EBIT ...

29/11/19
When we last wrote about Demant (Reduce, Denmark) a year ago, the hearing aids specialist was struggling to generate volume growth as its highly ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO